Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS ...Middle East

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET)...

Hence then, the article about phase ii opalescence study of tlx250 cdx in triple negative breast cancer to be presented at sabcs was published today ( Wednesday 29/11/2023 - 11:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS )

Also on site :

• One More Time With Feeling: Paramount-WBD Merger Opponents Aim To Slow Walk Skydance’s Paramount+ & HBO Max Consolidation
• Sony Wins Rights In Host Of International Territories To A24’s ‘You Can See Everything’ & ‘Primetime’
• Graceland Unveils Touching Vintage Photo Capturing Elvis Presley in His Favorite Role as Lisa Marie’s Dad